Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
diagnosis
|
| gptkbp:analyzes |
circulating cell-free DNA
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:detects |
biomarkers
mutations copy number alterations genomic alterations microsatellite instability tumor mutational burden rearrangements |
| gptkbp:developedBy |
gptkb:Foundation_Medicine
|
| gptkbp:enables |
targeted therapy selection
clinical trial enrollment |
| https://www.w3.org/2000/01/rdf-schema#label |
FoundationOne Liquid CDx
|
| gptkbp:intendedUse |
patients with solid tumors
|
| gptkbp:marketedAs |
gptkb:Foundation_Medicine
|
| gptkbp:regulates |
FDA-approved companion diagnostic
|
| gptkbp:reportsTo |
comprehensive genomic profile
|
| gptkbp:size |
324 genes
|
| gptkbp:type |
blood
liquid biopsy |
| gptkbp:usedFor |
cancer genomic profiling
|
| gptkbp:website |
https://www.foundationmedicine.com/tests/foundationone-liquid-cdx
|
| gptkbp:bfsParent |
gptkb:FoundationOne_Liquid
|
| gptkbp:bfsLayer |
7
|